Get the Stockscreener App
468.42
0.35%
1.63
After Hours:
469.98
1.56
+0.33%
Vertex Pharmaceuticals Inc stock is traded at $468.42, with a volume of 1.20M.
It is up +0.35% in the last 24 hours and up +7.80% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$466.79
Open:
$469.67
24h Volume:
1.20M
Relative Volume:
0.93
Market Cap:
$118.89B
Revenue:
$12.34B
Net Income/Loss:
$4.34B
P/E Ratio:
27.77
EPS:
16.8685
Net Cash Flow:
$3.71B
1W Performance:
+3.37%
1M Performance:
+7.80%
6M Performance:
+2.01%
1Y Performance:
+5.61%
1-Day Range:
$463.75
$470.82
1-Week Range:
$447.54
$470.82
52-Week Range:
$362.50
$507.92
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
468.42 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
618.03 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.40 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.18 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
169.51 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Upgrade | Maxim Group | Hold → Buy |
| Mar-10-26 | Initiated | Jefferies | Buy |
| Mar-10-26 | Reiterated | Oppenheimer | Outperform |
| Feb-13-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharma with clear analyst backing, shares supported by strong consensus estimates - AD HOC NEWS
Vertex Pharmaceuticals (VRTX) Stock After Strong Multi‑Year Run Is The Price Still Reasonable - Yahoo Finance
Positive Pediatric CASGEVY Data Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX) - Yahoo Finance
Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda - GlobeNewswire Inc.
Vertex Pharmaceuticals (NASDAQ:VRTX): A GARP Growth Stock with Reasonable Valuation and Strong Fundamentals - ChartMill
Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Vertex Pharmaceuticals Inc Stock (VRTX) Closed Up by 3.45% on Jun 22: What Signal Does It Send? - TradingKey
A Loophole Brings Cystic Fibrosis Patients a ‘Miracle Drug’ in Generic Form - The New York Times
2 Reasons to Like VRTX (and 1 Not So Much) - Yahoo Finance
How Strong Pediatric CASGEVY Data Could Impact Vertex Pharmaceuticals’ (VRTX) Gene Therapy Investment Narrative - simplywall.st
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks. - The Motley Fool
Vertex Pharma Stockweekly review in a strong biotech sector - AD HOC NEWS
Can Vertex's Kidney Pipeline Power Its Next Growth Phase? - TradingView
Nia Impact Solutions Fund's Vertex Pharmaceuticals Inc(VRTX) Holding History - GuruFocus
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance Singapore
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock - Yahoo Finance
Vertex Pharmaceuticals CFO’s case for thinking like a portfolio manager - CFO.com
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $585 - Moomoo
Fierce Biotech Layoff Tracker 2026: enGene halves workforce; Neumora cuts 35% - Fierce Biotech
Vertex Pharmaceuticals Inc. stock rises Monday, still underperforms market - MarketWatch
Vertex Pharma (NASDAQ: VRTX) notice: 4,062 shares proposed for resale on 06/15/2026 - Stock Titan
Vertex Pharma Stock (US92532F1003): Wall Street Analysts Lift Targets After VX-548 Progress - AD HOC NEWS
Vertex Pharma Stock (US92532F1003): Analyst sentiment and ownership moves keep VRTX in focus - AD HOC NEWS
Is It Time to Buy This Turnaround Pharma Stock? - NAI500
Vertex Pharmaceuticals (VRTX) Receives a Buy from Wells Fargo - The Globe and Mail
Swiss National Bank Reduces Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Meiji Yasuda America Inc Invests $1.91 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Aviva PLC Buys 11,322 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Extends Pediatric Pipeline As Shares Trade Below Consensus Targets - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts - Yahoo Finance
Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy Now? - Insider Monkey
Goldman Sachs Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $641 - Moomoo
Vertex CASGEVY pediatric data shows 100% success in CRISPR trials - grafa.com
Zions Bancorporation National Association UT Grows Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Reports Positive Data for Casgevy in Pediatrics - GuruFocus
Illinois Municipal Retirement Fund Reduces Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
LPL Financial LLC Has $125.53 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions - Business Wire
MFS Blended Research Core Equity Portfolio's Vertex Pharmaceuticals Inc(VRTX) Holding History - GuruFocus
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Vertex Pharmaceuticals stock (US92532F1003): Insider sale draws attention amid strong biotech pipeli - AD HOC NEWS
VRTX: Pipeline momentum in CF, pain, and kidney disease drives innovation-led growth outlook - TradingView
VRTX: Expanding CF, pain, and renal franchises with robust late-stage pipeline and innovation focus - TradingView
Vertex Pharma stock (US92532F1003): focus on cystic fibrosis growth and pipeline potential - AD HOC NEWS
Motley Fool Asset Management LLC Has $10.70 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Motley Fool Wealth Management LLC Decreases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
5.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):